Preventing Acute Kidney Injury and Improving Outcome in Critically Ill Patients Utilising Risk Prediction Score (PRAIOC-RISKS)
Preventing Acute Kidney Injury and Improving Outcome in Critically Ill Patients Utilising Risk Prediction Score - a Pilot Feasibility Randomized Controlled Trial
연구 개요
상세 설명
Background and rationale AKI is common in the intensive care unit .It contributes significantly to mortality and morbidity .the estimated incidence or AKI among critically ill patients is 30-40% and morality is high.
There is a well recognized gap between the optimal care and the delivered care regarding prevention and management of AKI.
The focus over the last few years has been on early detection. A panel of urinary biomarkers have proved helpful for early detection of AKI. However the cost and low specificity make no single one of them solely reliable .using a panel of bio-markers increases their specificity.
The concept of electronic alerts has been recently introduced. Some trials have been testing its impact on the outcome of AKI. The benefit of electronic alerts is still uncertain .A meta-analysis is currently underway to synthesize stronger evidence of electronic alerts benefit.
Another evolving area, is the development of risk score to predict AKI and and hence applying timely preventive measures.
KDIGO recommends applying preventive measures to high risk patients. However no study to date has tested risk scores based interventions
Hypothesis:
We will use the recently validated score to predict AKI in ICU patients. We will then apply preventive measures. To patients at risk .To our knowledge this is the first study to apply preventive interventions based on AKI risk score assessment
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Cairo, 이집트
- Cairo University Hospitals
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
All adult patients (≥18 year old) admitted to the intensive care unit and do not fulfill the criteria for the diagnosis of AKI by Kidney Disease Improving Global Outcome (KDIGO) definition
Exclusion Criteria:
- Patients who have already developed AKI at the time of intensive care unit ICU admission.
- Patients with insufficient medical records to obtain previous medical history
- Patients who lack mental capacity
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Observational
patients will be recruited to this arm to observe prospectively the incidence of AKI among critically ill patients.patients
will receive the standard care.No other intervention will be delivered
|
|
|
활성 비교기: Interventional
Patients in this arm will be subject to AKI risk score.
This risk score was recently developed and validated in Mayo clinic the intervention will be Measures to prevent AKI among critically ill patients
|
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of AKI
기간: during 7 days of ICU admission
|
We will compare the incidence rate between the interventional and the observational arm
|
during 7 days of ICU admission
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
30 day mortality
기간: 30 days
|
all cause mortality during 30 days of ICU admission or within 30 days of developement of AKI
|
30 days
|
|
Time to recovery after development of AKI
기간: 30 days
|
Time interval between the diagnosis of AKI and recovery of either blood chemistry or oliguria
|
30 days
|
|
Deterioration of AKI stage
기간: 30 days
|
Transition from initial stage KDIGO stage 1 to either 2 or 3 .Transition from initial stage 2 to 3
|
30 days
|
|
Duration of dialysis dependency
기간: 30 days
|
time patient remains dialysis-dependant after severe AKI.
|
30 days
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .